Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)

Completed

Conditions studied: Liver Neoplasms

In brief

Observational study to evaluate, under real-world practice conditions, the safety and effectiveness of regorafenib in patients diagnosed with unresectable hepatocellular carcinoma (uHCC)

Key facts

Study ID

NCT03289273

Run by

Bayer

People needed

1010

Starts

2017-09-13

Expected to finish

2022-06-21

Last updated by the study team

2023-06-13

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with confirmed diagnosis of unresectable HCC
• Physician-initiated decision to treat with regorafenib (prior to study enrollment)

You may not qualify if…

• Participation in an investigational program with interventions outside of routine clinical practice
• Past treatment with regorafenib

Where it is running

• Banner MD Anderson Cancer Center — Gilbert, Arizona, United States
• St. Joseph´s Hospital and Medical Center — Phoenix, Arizona, United States
• University of Florida Health — Gainesville, Florida, United States
• University of Louisville - Clinical Trials Unit — Louisville, Kentucky, United States
• University Medical Center — New Orleans, Louisiana, United States
• Mercy Medical Center — Baltimore, Maryland, United States
• University of Michigan — Ann Arbor, Michigan, United States
• Henry Ford Health System — Detroit, Michigan, United States
• Mayo Clinic — Rochester, Minnesota, United States
• Rutgers University — Newark, New Jersey, United States
• Roswell Park Cancer Institute — Buffalo, New York, United States
• C.R.Wood Cancer Center, Glen Falls Hospital — Glens Falls, New York, United States
• University of Cincinatti — Cincinnati, Ohio, United States
• Corporal Michael J. Crescenz VA Medical Center — Philadelphia, Pennsylvania, United States
• Einstein Medical Center — Philadelphia, Pennsylvania, United States
• UT Southwestern Medical Center — Dallas, Texas, United States
• MD Anderson Cancer Center — Houston, Texas, United States
• Many locations — Multiple Locations, Argentina
• Many locations — Multiple Locations, Austria
• Many locations — Multiple Locations, Belgium
• Many locations — Multiple Locations, Canada
• Many locations — Multiple Locations, China
• Many locations — Multiple Locations, Denmark
• Many locations — Multiple Locations, Egypt
• Many locations — Multiple Locations, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.